https://www.thebodypro.com/tag/croi-conference-on-retroviruses-and-opportunistic-infections

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding Img

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants Img

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults Img

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART Img

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART

"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies Img

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies

Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.

PREP in Pregnancy Does Not Increase Poor Birth Outcomes Img

PREP in Pregnancy Does Not Increase Poor Birth Outcomes

No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.

CROI 2017: A View from My Seat at the Table Img

CROI 2017: A View from My Seat at the Table

"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."

Bictegravir -- An Emerging Integrase Inhibitor Img

Bictegravir -- An Emerging Integrase Inhibitor

Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.

Doravirine versus Darunavir Img

Doravirine versus Darunavir

A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.

New Drugs, New Hope and Possible Timelines Img

New Drugs, New Hope and Possible Timelines

At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.